Morphine antinociception is enhanced in mdr1a gene-deficient mice

J Zong1, G M Pollack

  • 1Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina at Chapel Hill 27599-7360, USA.

Pharmaceutical Research
|August 24, 2000
PubMed
Abstract

Insights

P-glycoprotein (P-gp) reduces morphine

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • P-glycoprotein (P-gp) is a key efflux transporter in the central nervous system (CNS).
  • Previous research suggests P-gp influences opioid antinociception.

Purpose of the Study:

  • To investigate the role of P-gp in morphine antinociception.
  • To assess morphine's effects in mice lacking CNS P-gp expression (mdr1a gene knockout).

Main Methods:

  • Morphine administered to mdr1a(-/-) and wild-type mice.
  • Antinociception measured via tail-flick test.
  • Morphine concentrations analyzed in serum, brain, and spinal cord using HPLC.
  • Experiments included R(+)-verapamil, a P-gp inhibitor.

Main Results:

  • Morphine antinociception was significantly enhanced in mdr1a(-/-) mice (lower ED50).
  • Brain morphine concentrations were similar between groups.
  • R(+)-verapamil mimicked the effects seen in gene-deficient mice.
  • Spinal cord to serum morphine ratio was unaffected by P-gp deficiency.

Conclusions:

  • P-gp attenuates morphine's antinociceptive action.
  • This attenuation occurs by limiting morphine's distribution into the brain.
  • Findings support P-gp as a modulator of central opioid effects.

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...